NovoCure (NVCR) Cash from Investing Activities (2014 - 2026)

NovoCure's Cash from Investing Activities history runs 13 years deep, the most recent figure standing at $7.7 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 219.7% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $451.5 million (up 214.9% YoY), while the FY2025 annual figure was $437.3 million, up 411.8% from the prior year.
• Cash from Investing Activities came in at $7.7 million for Q1 2026 at NovoCure, down from $336.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $336.3 million in Q4 2025 to a low of -$374.4 million in Q2 2024.
• A 5-year average of $20.5 million and a median of $10.2 million in 2024 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities soared 6049.47% in 2022 and plunged 2594.39% in 2024, its largest moves.
• NovoCure's Cash from Investing Activities stood at -$128.1 million in 2022, then jumped by 176.92% to $98.5 million in 2023, then plunged by 122.55% to -$22.2 million in 2024, then soared by 1614.23% to $336.3 million in 2025, then plunged by 97.7% to $7.7 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $7.7 million, $336.3 million, and $71.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison